Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.This is an entirely free service. No payments are to be made.
Here is the latest stock price and chart of J.B.Chemicals. For more details, see the J.B.Chemicals company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
|Live BSE Quotes||Mar 30, 2017 11:59:00 AM|
|Price (Rs)349.50||Open (Rs) 349.00||High (Rs) 352.00||Low (Rs) 346.45|
|% Change0.55||Volume 1,892||Value (Rs) 661,254||52-Week H/L 403.60 / 231.00|
|Live NSE Quotes||Mar 30, 2017 11:59:49 AM|
|Price (Rs)348.50||Open (Rs) 353.90||High (Rs) 353.95||Low (Rs) 345.55|
|% Change0.17||Volume 24,443||Value (Rs) 8,531,340||52-Week H/L 403.90 / 231.30|
|EPS (Rs)* 20.52||P/E Ratio (x) 17.03||Market Cap (Rs m) 29,637.60||P/BV (x) 2.71|
|*Trailing 12 months earnings, excluding extraordinary / exceptional items.||BSE Sensex | CNX Nifty|
|J.B.Chemicals Share Price Chart (Rs) - 1 Year|
Quote & Graph
S&P BSE SENSEX
Asian equity markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.25% while the Hang Seng is down 0.50%. The Shanghai Composite is trading lower by 1.13%.
Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.
Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.
Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.
Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.More Views on News
The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.
Apurva breaks down the historic performance of initial public offerings in the context of D-Mart.
Many investors have got anchored to a selling price which has got nothing to do with the current state of the real estate market
PersonalFN provides a prudent investment strategy to invest in mutual funds as market scales a new high.
This is why RBI's new strategy is ineffective to deal with bad debt menace.More